The Ensign Group, Inc. (ENSG) P/E Ratio History
Historical price-to-earnings valuation from 2007 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, The Ensign Group, Inc. (ENSG) trades at a price-to-earnings ratio of 36.7x, with a stock price of $214.17 and trailing twelve-month earnings per share of $5.57.
The current P/E is 40% above its 5-year average of 26.2x. Over the past five years, ENSG's P/E has ranged from a low of 20.5x to a high of 34.8x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, ENSG trades at a 55% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
The PEG ratio of 2.66 (P/E divided by 14% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, ENSG commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ENSG DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Post-acute and senior care peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ENSGThe Ensign Group, Inc. | $12B | 36.7 | 2.66 | +14% |
EHCEncompass Health Corporation | $11B | 19.4 | 1.36 | +24%Best |
NHCNational HealthCare Corporation | $3B | 21.3 | 0.93Best | +17% |
SEMSelect Medical Holdings Corporation | $2B | 12.9Lowest | - | -30% |
PNTGThe Pennant Group, Inc. | $1B | 40.1 | 3.99 | +18% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $172.77 | $5.59 | 30.9x | +64% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $154.26 | $5.51 | 28.0x | +48% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $129.40 | $5.29 | 24.5x | +30% |
| FY2024 Q4 | $132.86 | $5.11 | 26.0x | +38% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $143.82 | $4.13 | 34.8x | +85% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $123.69 | $3.90 | 31.7x | +68% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $124.42 | $3.80 | 32.7x | +74% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $112.21 | $3.66 | 30.7x | +63% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $92.93 | $4.37 | 21.3x | +13% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $95.46 | $4.25 | 22.5x | +19% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $95.54 | $4.14 | 23.1x | +22% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $94.61 | $3.98 | 23.8x | +26% |
Average P/E for displayed period: 18.9x
See ENSG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ENSG Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ENSG vs AGIO
See how ENSG stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ENSG stock overvalued or undervalued?
ENSG trades at 36.7x P/E, above its 5-year average of 26.2x. The 100th percentile ranking indicates a premium to historical valuation.
How does ENSG's valuation compare to peers?
The Ensign Group, Inc. P/E of 36.7x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is ENSG's PEG ratio?
ENSG PEG ratio is 2.66. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2007-2025.